Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ABP 980, a biosimilar antibody for trastuzumab

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 2868

Dr Richard Markus - Amgen, Conejo Valley, USA

Dr Markus talks with ecancer at the ESMO 2017 Congress in Madrid about ABP 980 and its efficiency compared to trastuzumab in the treatment of patients with HER2 positive early breast cancer. 

He discusses the structure, function, and pharmacokinetics of the biosimilar compared to trastuzumab, and outlines the clinical equivalencies met in a series of trials.

Dr Markus also considers the clinical and economic significance of treatment choice in managing breast cancer, with ABP 980 submitted for approval to market, making it potentially the first available biosimilar antibody.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content. 

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence